Demographic profile (n) | No dysfunction (n = 82) | Dysfunction (n = 28) | p-value | Crude odd ratio (CI) | Adjusted OR (CI) |
Age <5 yrs (46) >5yrs (64) |
37 (45%) 45 (55%) |
9 (32%) 19 (68%) |
0.276 |
1.736 (0.703 - 4.289) |
|
Sex Males (75) Females (35) |
54 (66%) 28 (34%) |
21(75%) 7 (25%) |
0.487 |
1.556 (0.590 - 4.102) |
|
Type of malignancy Hematological (94) Solid tumors (16) |
71 (87%) 11 (13%) |
23 (82%) 5 (18%) |
0.756 |
1.403 (0.441 - 4.463) |
|
Daunorubicin Daunorubicin + Doxorubicin | 6 (7%) 76 (93%) | 10 (36%) 18 (64%) | 0.001 | 7.037 (2.262 - 21.895) | - |
*Mode of delivery Bolus (106) Infusion (4) |
81 (99%) 1(1%) |
25(89%) 3 (11%) |
0.048 |
9.72 (0.968 - 97.647) | - |
Cumulative anthracycline dose <300 mg (95) >300 mg (15) |
78 (95%) 4 (5%) |
17 (61%) 11 (39%) |
<0.001 | 12.618 (3.583 - 44.43) | 2.25 (0.032 - 0.522) |
Radiation therapy (24) | 13 (16%) | 11 (39%) | 0.009 | 3.434 (1.312 - 8.992) | 3.46 (0.115 - 0.427) |
*Down’s syndrome (8) | 5 (6%) | 3 (11%) | 0.331 | 1.848 (0.412 - 8.288) |
|
Sepsis (47) | 28 (34%) | 19 (68%) | 0.002 | 4.071 (1.631 - 10.166) | 2.58 (0.040 - 0.305) |